Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

BACKGROUND: Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase IIa trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhar, Sriram, Liu, Hao, Pham, Tuyet-Hang, Damera, Gautam, Newbold, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339432/
https://www.ncbi.nlm.nih.gov/pubmed/30658649
http://dx.doi.org/10.1186/s12931-018-0968-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339432/
https://www.ncbi.nlm.nih.gov/pubmed/30658649
http://dx.doi.org/10.1186/s12931-018-0968-8

Ejemplares similares